Latest Commercialisation News

Bio-Gene Technology has raised approximately A$3.275 million through its second tranche placement and share purchase plan underwriting, issuing over 51 million new shares and 69 million options to investors.

ReNerve Limited has gained marketing approval for its flagship NervAlign Nerve Cuff in India, marking a critical milestone in its global expansion and enabling commercial rollout in one of the world's largest nerve repair markets.

Metallium Limited has appointed key board members and executives to strengthen governance and operational capacity as it advances its Flash Joule Heating technology towards commercialisation in the US.

Flynn Gold is kicking off a 2,500m drilling campaign at its Brilliant Prospect in northeast Tasmania, aiming to convert promising trench assay results into a formal Mineral Resource and fast-track project development.

Wide Open Agriculture (ASX: WOA) has taken a significant step towards a capital-light production model by signing a non-binding framework agreement with Proeon Foods for contract manufacturing of its lupin-based ingredients, including exclusive Indian distribution rights.

BPM Minerals has kicked off a record 20,000m reverse circulation drilling campaign at its Forelands Gold Project in Western Australia, targeting a maiden JORC-compliant resource at Beachcomber and preparing for maiden drilling at Bonnie & Clyde.

EVE Health Group has progressed its Libbo pilot clinical study for erectile dysfunction with dosing set for Q4 2026 and achieved a major solubility breakthrough for apixaban, while appointing Ben Rohr as CEO to drive commercial growth.

AVITA Medical posted robust Q2 2026 results with 18% revenue growth, driven by RECELL and supported by Cohealyx and PermeaDerm, and now expects to reach cash flow breakeven by year-end.

Viking Mines has uncovered significant tungsten mineralisation in historical rock stockpiles at its Linka Tungsten Project, Nevada, with assay results reaching 1.8% WO3, well above the historical mined average. The findings open the door to potential ore sorting applications and advance the project towards a brownfields restart.

Acrux Limited spotlighted its Female Testosterone Metered Dose Transdermal System (MDTS) at the Bioshares Biotech Summit, revealing positive Phase II data and outlining a clear regulatory and commercial roadmap targeting Hypoactive Sexual Desire Disorder (HSDD) in women.

Osteopore has inked a three-year distribution agreement with Al-Umnia Medical to bring its 3D-printed orthopaedic implants to five Gulf countries, targeting a rapidly expanding regional market.

Dimerix CEO Dr Nina Webster detailed the company’s geographic and product diversification at the Bioshares Summit, spotlighting the commercial potential of DMX-200 and the newly acquired Phase 2 asset DMX-652 targeting acute kidney injury.